REG - Avacta Group PLC - Notice of Interim Results

AvactaAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250915:nRSO3046Za&default-theme=true

RNS Number : 3046Z  Avacta Group PLC  15 September 2025

Notice of Interim Results and Investor Presentation

 

Change of Date, Time and Location of ESMO Abstract Presentation

 

 

LONDON AND PHILADELPHIA - September 15, 2025 -  Avacta Group plc (AIM: AVCT)
a life sciences company developing innovative, targeted oncology drugs,
confirms it will announce its unaudited interim results for the six months
ended June 30, 2025 ("HY25"), on September 30, 2025.

 

Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial
Officer will also deliver a live presentation via Investor Meet Company at
14:00 BST on the day.

 

The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA
GROUP PLC via: AVCT - AVACTA GROUP PLC | Investor Meet Company
(https://www.investormeetcompany.com/companies/avacta-group-plc)

 

Investors who already follow Avacta on the Investor Meet Company platform will
automatically be invited.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard
up until September 30 09:00 BST, or at any time during the live presentation.

 

The Company will also post the results presentation on its website at the
following page: https://avacta.com/investors/investor-resources/
(https://avacta.com/investors/investor-resources/) .

 

ESMO Congress Update

 

The Company confirms that the date, time and location of the abstract being
presented at the European Society for Medical Oncology (ESMO) Congress, taking
place from October 17-21, 2025, has changed. The updated details are included
below:

 

Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein
(FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide
drug conjugate in patients with FAP-positive solid tumors

Session Title: Developmental Therapeutics

Session Date and Time: 19 October, 12.00-12.45

Location: Hall 25

Abstract Presentation Number: 964P

Speaker: William D. Tap

 

-Ends-

 

For further information from Avacta, please contact:

 

 Peel Hunt (Nomad and Joint Broker)                          www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare (Europe/UK media and investors)             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto

 Carly Scaduto Consulting

 

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUSSKRVRUKAAR